niacinamide and olaparib

niacinamide has been researched along with olaparib in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Lehtiö, L; Narwal, M; Venkannagari, H	1
Ellis, LM; Harris, AL; Jayson, GC; Kerbel, R	1
Baks-Te Bulte, L; Brundel, BJJM; de Groot, NMS; de Vries, AAF; Henning, RH; Hoogstra-Berends, F; Hu, X; Lanters, EAH; Li, J; Liu, J; Malik, NU; Pijnappels, DA; Tolouee, M; van Marion, DMS; van Roon, AM; Wiersma, M; Zhang, D	1

Reviews

1 review(s) available for niacinamide and olaparib

Article	Year
Antiangiogenic therapy in oncology: current status and future directions. Lancet (London, England), 2016, Jul-30, Volume: 388, Issue:10043 Topics: Angiogenesis Inhibitors; Angiopoietin-1; Biomarkers, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, TIE-2; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A	2016

Article

Year

Antiangiogenic therapy in oncology: current status and future directions.

Lancet (London, England), 2016, Jul-30, Volume: 388, Issue:10043

Topics: Angiogenesis Inhibitors; Angiopoietin-1; Biomarkers, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, TIE-2; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A

2016

Other Studies

2 other study(ies) available for niacinamide and olaparib

Article	Year
Structural basis of selective inhibition of human tankyrases. Journal of medicinal chemistry, 2012, Feb-09, Volume: 55, Issue:3 Topics: Catalytic Domain; Crystallography, X-Ray; Enzyme Assays; Humans; Models, Molecular; Niacinamide; Phthalazines; Piperazines; Protein Binding; Protein Conformation; Quinolines; Structure-Activity Relationship; Tankyrases	2012
DNA damage-induced PARP1 activation confers cardiomyocyte dysfunction through NAD Nature communications, 2019, 03-21, Volume: 10, Issue:1 Topics: Animals; Atrial Fibrillation; Benzimidazoles; Cells, Cultured; DNA Damage; Drosophila melanogaster; Enzyme Activation; Heart Atria; Humans; Larva; Mice; Models, Cardiovascular; Myocardial Contraction; Myocytes, Cardiac; NAD; Niacinamide; Oxidative Stress; Pacemaker, Artificial; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Pupa; Rats; Rats, Wistar	2019

Article

Year

Structural basis of selective inhibition of human tankyrases.

Journal of medicinal chemistry, 2012, Feb-09, Volume: 55, Issue:3

Topics: Catalytic Domain; Crystallography, X-Ray; Enzyme Assays; Humans; Models, Molecular; Niacinamide; Phthalazines; Piperazines; Protein Binding; Protein Conformation; Quinolines; Structure-Activity Relationship; Tankyrases

2012

DNA damage-induced PARP1 activation confers cardiomyocyte dysfunction through NAD

Nature communications, 2019, 03-21, Volume: 10, Issue:1

Topics: Animals; Atrial Fibrillation; Benzimidazoles; Cells, Cultured; DNA Damage; Drosophila melanogaster; Enzyme Activation; Heart Atria; Humans; Larva; Mice; Models, Cardiovascular; Myocardial Contraction; Myocytes, Cardiac; NAD; Niacinamide; Oxidative Stress; Pacemaker, Artificial; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Pupa; Rats; Rats, Wistar

2019